SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Idt Corp – ‘10-Q’ for 1/31/17 – ‘R14’

On:  Monday, 3/13/17, at 5:15pm ET   ·   For:  1/31/17   ·   Accession #:  1213900-17-2245   ·   File #:  1-16371

Previous ‘10-Q’:  ‘10-Q’ on 12/12/16 for 10/31/16   ·   Next:  ‘10-Q’ on 6/9/17 for 4/30/17   ·   Latest:  ‘10-Q’ on 3/11/24 for 1/31/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/17  Idt Corp                          10-Q        1/31/17   68:3.8M                                   Edgar Agents LLC/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    382K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
12: R1          Document and Entity Information                     HTML     39K 
13: R2          Consolidated Balance Sheets                         HTML    125K 
14: R3          Consolidated Balance Sheets (Parenthetical)         HTML     42K 
15: R4          Consolidated Statements of Income (Unaudited)       HTML     80K 
16: R5          Consolidated Statements of Comprehensive Income     HTML     44K 
                (Unaudited)                                                      
17: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML    117K 
18: R7          Basis of Presentation                               HTML     24K 
19: R8          Zedge Spin-Off                                      HTML     31K 
20: R9          Investment in Cornerstone Pharmaceuticals, Inc.     HTML     30K 
21: R10         Marketable Securities                               HTML     59K 
22: R11         Fair Value Measurements                             HTML     40K 
23: R12         Derivative Instruments                              HTML     35K 
24: R13         Equity                                              HTML     47K 
25: R14         Earnings Per Share                                  HTML     36K 
26: R15         Revolving Credit Loan Payable                       HTML     24K 
27: R16         Accrued Severance Expense                           HTML     21K 
28: R17         Accumulated Other Comprehensive Loss                HTML     32K 
29: R18         Business Segment Information                        HTML     51K 
30: R19         Commitments and Contingencies                       HTML     41K 
31: R20         Other (Expense) Income, Net                         HTML     28K 
32: R21         Income Taxes                                        HTML     23K 
33: R22         Recently Issued Accounting Standard Not Yet         HTML     32K 
                Adopted                                                          
34: R23         Zedge Spin-Off (Tables)                             HTML     26K 
35: R24         Marketable Securities (Tables)                      HTML     87K 
36: R25         Fair Value Measurements (Tables)                    HTML     36K 
37: R26         Derivative Instruments (Tables)                     HTML     25K 
38: R27         Equity (Tables)                                     HTML     40K 
39: R28         Earnings Per Share (Tables)                         HTML     45K 
40: R29         Accumulated Other Comprehensive Loss (Tables)       HTML     27K 
41: R30         Business Segment Information (Tables)               HTML     60K 
42: R31         Commitments and Contingencies (Tables)              HTML     28K 
43: R32         Other (Expense) Income, Net (Tables)                HTML     31K 
44: R33         Zedge Spin-Off (Details)                            HTML     27K 
45: R34         Investment in Cornerstone Pharmaceuticals, Inc.     HTML     87K 
                (Details)                                                        
46: R35         Marketable Securities (Details)                     HTML     64K 
47: R36         Marketable Securities (Details 1)                   HTML     34K 
48: R37         Marketable Securities (Details 2)                   HTML     44K 
49: R38         Marketable Securities (Details Textual)             HTML     38K 
50: R39         Fair Value Measurements (Details)                   HTML     30K 
51: R40         Fair Value Measurements (Details Textual)           HTML     22K 
52: R41         Derivative Instruments (Details)                    HTML     21K 
53: R42         Equity (Details)                                    HTML     62K 
54: R43         Equity (Details Textual)                            HTML     60K 
55: R44         Earnings Per Share (Details)                        HTML     33K 
56: R45         Earnings Per Share (Details 1)                      HTML     22K 
57: R46         Revolving Credit Loan Payable (Details)             HTML     46K 
58: R47         Accrued Severance Expense (Details)                 HTML     26K 
59: R48         Accumulated Other Comprehensive Loss (Details)      HTML     48K 
60: R49         Business Segment Information (Details)              HTML     42K 
61: R50         Business Segment Information (Details Textual)      HTML     20K 
62: R51         Commitments and Contingencies (Details)             HTML     28K 
63: R52         Commitments and Contingencies (Details Textual)     HTML     40K 
64: R53         Other (Expense) Income, Net (Details)               HTML     33K 
65: R54         Income Taxes (Details)                              HTML     24K 
67: XML         IDEA XML File -- Filing Summary                      XML    117K 
66: EXCEL       IDEA Workbook of Financial Reports                  XLSX     61K 
 6: EX-101.INS  XBRL Instance -- idt-20170131                        XML   1.04M 
 8: EX-101.CAL  XBRL Calculations -- idt-20170131_cal                XML    137K 
 9: EX-101.DEF  XBRL Definitions -- idt-20170131_def                 XML    382K 
10: EX-101.LAB  XBRL Labels -- idt-20170131_lab                      XML    931K 
11: EX-101.PRE  XBRL Presentations -- idt-20170131_pre               XML    600K 
 7: EX-101.SCH  XBRL Schema -- idt-20170131                          XSD    127K 
68: ZIP         XBRL Zipped Folder -- 0001213900-17-002245-xbrl      Zip    100K

‘R14’   —   Earnings Per Share

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v3.6.0.2
Earnings Per Share
 6 Months Ended
Earnings Per Share [Abstract]  
Earnings Per Share

Note 8—Earnings Per Share

 

Basic earnings per share is computed by dividing net income attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted earnings per share is computed in the same manner as basic earnings per share, except that the number of shares is increased to include restricted stock still subject to risk of forfeiture and to assume exercise of potentially dilutive stock options using the treasury stock method, unless the effect of such increase is anti-dilutive.

 

The weighted-average number of shares used in the calculation of basic and diluted earnings per share attributable to the Company’s common stockholders consists of the following:

 

  Three Months Ended
January 31,		  Six Months Ended 
January 31,		 
  2017  2016  2017  2016 
  (in thousands) 
Basic weighted-average number of shares  22,768   22,799   22,740   22,867 
Effect of dilutive securities:                
Stock options  77   —   58   — 
Non-vested restricted Class B common stock  118   —   133   17 
Diluted weighted-average number of shares  22,963   22,799   22,931   22,884 

 

The following outstanding stock options were excluded from the calculation of diluted earnings per share because the exercise price of the stock option was greater than the average market price of the Company’s stock during the period:

 

  Three Months Ended
January 31,		  Six Months Ended 
January 31,		 
  2017  2016  2017  2016 
  (in thousands) 
Shares excluded from the calculation of diluted earnings per share  3   265   18   266 

Dates Referenced Herein

This ‘10-Q’ Filing    Date    Other Filings
Filed on:3/13/17None on these Dates
For Period end:1/31/17
 List all Filings 
↑Top
Filing Submission 0001213900-17-002245   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 17, 8:59:12.1am ET